ArticleScientific reports2026
Domain adaptation, self-supervision, and generative augmentation enhance GNNs for breast cancer prediction.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prototype contrastive and adversarial alignment for heterogeneous domain adaptation.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer presents substantial molecular heterogeneity, requiring accurate subtype classification, receptor-status prediction, and survival estimation for precision care. Existing machine-learning models often fail to generalize across cohorts or adapt to rare subtypes. We propose a unified graph neural network (GNN) framework that integrates multi-task learning, domain-adversarial adaptation, contrastive self-supervision, few-shot meta-learning, and generative augmentation. Gene-expression data from TCGA-BRCA (1084 samples) and METABRIC (1980 samples) were mapped onto gene-centric PPI graphs and patient-similarity graphs. A shared encoder (including Graph Transformer variants) jointly predicts intrinsic subtypes (Luminal A, Luminal B, HER2-enriched, Basal-like), ER/PR/HER2 biomarkers, and overall survival (OS) using a Cox proportional hazards head. Validation included fivefold cross-validation and strict TCGA → METABRIC transfer testing. The multi-task Graph Transformer achieved subtype F1 = 0.872, ER/PR/HER2 AUCs of 0.960/0.943/0.918, and C-index = 0.721. Domain adaptation improved external subtype F1 from 0.738 to 0.801. For the HER2-enriched subtype, MAML enabled few-shot prediction with F1 = 0.782, while MolGAN augmentation increased HER2 AUC to 0.935. GNNExplainer highlighted biologically consistent drivers, including ESR1, ERBB2, and PGR, aligning with known hormonal and HER2 signaling mechanisms. This study introduces a comprehensive, interpretable GNN framework that unifies subtyping, biomarker prediction, and survival modeling while improving cross-cohort robustness and rare-subtype adaptation. The combination of multi-task learning, domain adaptation, self-supervision, and generative augmentation demonstrates strong potential for clinically actionable decision support.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.